28/08/2025
The ๐ง๐ฟ๐ฎ๐ถ๐ป๐ถ๐ป๐ด ๐ผ๐ป ๐ฃ๐ต๐ฎ๐ฟ๐บ๐ฎ๐ฐ๐ผ๐๐ถ๐ด๐ถ๐น๐ฎ๐ป๐ฐ๐ฒ, ๐ ๐ผ๐ฑ๐ฒ๐น-๐ฏ๐ฎ๐๐ฒ๐ฑ ๐ฆ๐๐ฎ๐ฏ๐ถ๐น๐ถ๐๐, ๐ฎ๐ป๐ฑ ๐๐ฒ๐๐ฒ๐ฐ๐๐ถ๐ผ๐ป ๐ผ๐ณ ๐๐บ๐ฝ๐๐ฟ๐ถ๐๐ถ๐ฒ๐ ๐ถ๐ป ๐ฃ๐ต๐ฎ๐ฟ๐บ๐ฎ๐ฐ๐ฒ๐๐๐ถ๐ฐ๐ฎ๐น ๐ฃ๐ฟ๐ผ๐ฑ๐๐ฐ๐๐ ๐ถ๐ป ๐๐ต๐ฒ ๐๐ถ๐๐๐ฟ๐ถ๐ฏ๐๐๐ถ๐ผ๐ป ๐ฆ๐๐ฝ๐ฝ๐น๐ ๐๐ต๐ฎ๐ถ๐ป initiated by the Institute of Pharmaceutical Sciences of the National Institutes of Health, in partnership with the Disease Prevention and Control Bureau (DPCB) of the Department of Health, has successfully concluded its ๐ณ๐ผ๐๐ฟ ๐๐ฟ๐ฎ๐ถ๐ป๐ถ๐ป๐ด ๐ฟ๐๐ป๐ held on ๐๐๐ป๐ฒ ๐ฎโ๐ฑ (๐ก๐๐ฅ), ๐๐๐ป๐ฒ ๐ญ๐ฒโ๐ญ๐ต (๐๐๐๐ผ๐ป), ๐๐๐น๐ ๐ญ๐ฐโ๐ญ๐ณ (๐ฉ๐ถ๐๐ฎ๐๐ฎ๐), ๐ฎ๐ป๐ฑ ๐๐๐ด๐๐๐ ๐ญ๐ญโ๐ญ๐ฐ, ๐ฎ๐ฌ๐ฎ๐ฑ (๐ ๐ถ๐ป๐ฑ๐ฎ๐ป๐ฎ๐ผ).
With the participation of ๐ผ๐๐ฒ๐ฟ ๐ฎ,๐ฌ๐ฌ๐ฌ ๐ฝ๐ฟ๐ผ๐ณ๐ฒ๐๐๐ถ๐ผ๐ป๐ฎ๐น๐ across all training runs, including regulators, clinical researchers, pharmacists, nurses, medical doctors, chemists, chemical engineers, and pharmacovigilance professionals, this capacity-building initiative has provided an invaluable platform to enhance technical competencies in safeguarding the pharmaceutical supply chain.
The training program covered four comprehensive modules:
1๏ธโฃ Basic Pharmacovigilance and Pharmacovigilance Practices
2๏ธโฃ Applied Pharmacovigilance, Risk Management Plan, Pharmacovigilance Plan, and Causality Assessment
3๏ธโฃ Model-based Stability Testing
4๏ธโฃ Impurity Detection in Pharmaceutical Products
We are deeply grateful to our distinguished speakers, ๐ ๐. ๐๐ฟ๐ถ๐๐ฒ๐น๐ฑ๐ฎ ๐ฉ. ๐๐ผ๐๐๐ธ๐ฎ, ๐๐ฟ. ๐๐ฒ๐ฟ๐ฒ๐น๐๐ป ๐. ๐๐ฎ๐ฐ๐๐น๐ฎ, ๐ ๐ฟ. ๐๐ฎ๐ฟ๐น๐ผ ๐. ๐ฃ๐ฒ๐ฟ๐ฒ๐๐ฒ, ๐ฎ๐ป๐ฑ ๐๐ฟ. ๐๐ฒ๐ผ๐ป๐ฒ๐น ๐ . ๐ฆ๐ฎ๐ป๐๐ผ๐, for their expertise and dedication in guiding the participants throughout this program.
As emphasized by our Project Leader, Dr. Imelda G. Peรฑa, ๐ฝ๐ต๐ฎ๐ฟ๐บ๐ฎ๐ฐ๐ผ๐๐ถ๐ด๐ถ๐น๐ฎ๐ป๐ฐ๐ฒ ๐ถ๐ ๐ป๐ผ๐ ๐บ๐ฒ๐ฟ๐ฒ๐น๐ ๐ฎ ๐ฟ๐ฒ๐ด๐๐น๐ฎ๐๐ผ๐ฟ๐ ๐ผ๐ฏ๐น๐ถ๐ด๐ฎ๐๐ถ๐ผ๐ป, ๐ฏ๐๐ ๐ฎ ๐๐ต๐ฎ๐ฟ๐ฒ๐ฑ ๐ฟ๐ฒ๐๐ฝ๐ผ๐ป๐๐ถ๐ฏ๐ถ๐น๐ถ๐๐. Strengthening our systems and practices ensures that every medicine reaching Filipino patients is safe, effective, and of the highest quality.
We extend our appreciation to all participants for their active engagement, and we look forward to building on this momentum towards stronger regulatory systems, better pharmacovigilance practices, and improved patient safety outcomes!